Earnings Releases·Nov 10, 2026, 7:15 AM ET

CalciMedica — Third Quarter 2026 Earnings Summary

Net loss narrowed to $1.7 million ($0.24/share) for Q3 2026 from $7.8 million ($2.59/share) in 2025, driven by a shift from $2.2 million in other expenses to $3.1 million in other income; stockholders' equity turned positive to $4.2 million as liabilities fell to $10.1 million.
Cash and investments of $13.8 million are projected to fund operations through the second half of 2027, while R&D expenses decreased to $2.3 million in Q3 2026 from $3.9 million in the prior year period.
Management anticipates key catalysts in mid-2027, including Phase 1b data for Auxora in pulmonary hypertension and the CM5480 IND submission, with Phase 2b trial initiation in acute pancreatitis contingent on additional financing.
A 1-for-5 reverse stock split effective August 31, 2026, reduced shares outstanding to 6.9 million to meet Nasdaq minimum bid price requirements, while the KOURAGE trial for acute kidney injury remains paused with no plans to restart.